Dorzolamide Hydrochloride Solution label

Dorzolamide Hydrochloride Solution

Dorzolamide Hydrochloride Solution Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

Dorzolamide hydrochloride ophthalmic solution is a sulfonamide and, although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration with dorzolamide hydrochloride ophthalmic solution. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

History

There is currently no drug history available for this drug.

Other Information

Dorzolamide hydrochloride ophthalmic solution is a carbonic anhydrase inhibitor formulated for topical ophthalmic use.

Dorzolamide hydrochloride is described chemically as: (4S–trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride. Dorzolamide hydrochloride is optically active. The specific rotation is

                                                                       25° 
                                                                 α                        (C=1, water) = ∼‑17°.
                                                                       405

Its empirical formula is C10H16N2O4S3•HCl and its structural formula is:

chemical structure

Dorzolamide hydrochloride has a molecular weight of 360.9 and a melting point of about 264°C. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol.

Dorzolamide hydrochloride ophthalmic solution is supplied as a sterile, isotonic, buffered, slightly viscous, aqueous solution of dorzolamide hydrochloride. The pH of the solution is approximately 5.6, and the osmolarity is 260-330 mOsM. Each mL of dorzolamide hydrochloride ophthalmic solution 2% contains 20 mg dorzolamide (22.3 mg of dorzolamide hydrochloride). Inactive ingredients are hydroxyethyl cellulose, mannitol, sodium citrate dihydrate, sodium hydroxide (to adjust pH) and water for injection. Benzalkonium chloride 0.0075% is added as a preservative.

Dorzolamide Hydrochloride Solution Manufacturers

  • Prasco Laboratories
    Dorzolamide Hydrochloride Solution | Prasco Laboratories
    No Recall

    Dorzolamide Hydrochloride Solution | Prasco Laboratories

    Dorzolamide Hydrochloride Solution | Prasco Laboratories

    The dose is one drop of dorzolamide hydrochloride ophthalmic solution in the affected eye(s) three times daily.

    Dorzolamide hydrochloride ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.

  • Dorzolamide Hydrochloride Solution | Teva Pharmaceuticals Usa Inc
    No Recall

    Dorzolamide Hydrochloride Solution | Teva Pharmaceuticals Usa Inc

    Dorzolamide Hydrochloride Solution | Teva Pharmaceuticals Usa Inc

    The dose is one drop of dorzolamide hydrochloride ophthalmic solution, 2% in the affected eye(s) three times daily. Dorzolamide hydrochloride ophthalmic solution, 2% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.